Details for: LYAR
Gene ID: 55646
Gene Type: Protein-coding - A gene that serves as a template for producing a messenger RNA (mRNA) molecule, which is then translated into a functional protein.
Symbol: LYAR
Ensembl ID: ENSG00000145220
Description: Ly1 antibody reactive
Selected Context(s): Overall
Cell Significance Landscape
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 47.14rCSI 32.77%PRS 47.33
-
CSI 24.19rCSI 18.81%PRS 55.4
-
CSI 16.83rCSI 20.39%PRS 37.32
-
CSI 15.46rCSI 12.49%PRS 50.65
-
CSI 14.17rCSI 12.79%PRS 36.37
-
CSI 13.78rCSI 16.19%PRS 81.45
-
CSI 12.13rCSI 21.89%PRS 66.79
-
CSI 11.26rCSI 17.55%PRS 66.74
-
CSI 11.08rCSI 11.57%PRS 70.63
-
CSI 8.95rCSI 9.27%PRS 44.98
-
CSI 8.71rCSI 11.14%PRS 73.84
-
CSI 7.38rCSI 4.97%PRS 48.86
-
CSI 7rCSI 5.32%PRS 50
-
CSI 6.88rCSI 15.37%PRS 45.5
-
CSI 6.76rCSI 8.17%PRS 46.49
-
CSI 6.66rCSI 4.44%PRS 65.73
-
CSI 6.22rCSI 16.5%PRS 52.89
-
CSI 5.86rCSI 6.6%PRS 55.29
-
CSI 5.84rCSI 29.28%PRS 49.87
-
CSI 5.65rCSI 4.52%PRS 60.76
-
CSI 5.52rCSI 24.29%PRS 34.25
-
CSI 5.44rCSI 7.48%PRS 60.03
-
CSI 4.78rCSI 16.97%PRS 76.59
-
CSI 4.33rCSI 3.63%PRS 44.61
-
CSI 4.3rCSI 5.52%PRS 37.75
-
CSI 4.23rCSI 8.22%PRS 41.29
-
CSI 4.22rCSI 24.21%PRS 50.51
-
CSI 4.18rCSI 5.71%PRS 44.03
-
CSI 4.08rCSI 3.08%PRS 51.04
-
CSI 4.02rCSI 3.72%PRS 59.67
-
CSI 3.96rCSI 2.34%PRS 53.34
-
CSI 3.95rCSI 3.11%PRS 45.47
-
CSI 3.87rCSI 3.8%PRS 54.26
-
CSI 3.75rCSI 5.31%PRS 48.91
-
CSI 3.55rCSI 3.12%PRS 44.33
-
CSI 3.44rCSI 5.43%PRS 40.44
-
CSI 3.41rCSI 3.28%PRS 40.11
-
CSI 3.4rCSI 4.07%PRS 59.27
-
CSI 3.28rCSI 2.71%PRS 40.35
-
CSI 3.21rCSI 4.38%PRS 67.43
-
CSI 3.14rCSI 2.08%PRS 43.6
-
CSI 3.13rCSI 3.08%PRS 68.09
-
CSI 3.1rCSI 3.19%PRS 56.81
-
CSI 2.88rCSI 6.33%PRS 43.3
-
CSI 2.87rCSI 5.44%PRS 73.83
-
CSI 2.87rCSI 2.06%PRS 51.67
-
CSI 2.81rCSI 2.56%PRS 54.05
-
CSI 2.73rCSI 2.64%PRS 31.05
-
CSI 2.67rCSI 2.48%PRS 39.31
-
CSI 2.61rCSI 2.47%PRS 40.67
-
CSI 2.6rCSI 2.39%PRS 46.34
-
CSI 2.6rCSI 11.27%PRS 55.24
-
CSI 2.58rCSI 3.02%PRS 54.16
-
CSI 2.57rCSI 5.83%PRS 45.25
-
CSI 2.56rCSI 2.95%PRS 34.63
-
CSI 2.41rCSI 4.84%PRS 30.56
-
CSI 2.36rCSI 3.89%PRS 44.6
-
CSI 2.32rCSI 1.83%PRS 28.54
-
CSI 2.27rCSI 1.59%PRS 41.23
-
CSI 2.26rCSI 12.21%PRS 54.69
-
CSI 2.22rCSI 2.21%PRS 34.27
-
CSI 2.18rCSI 3.49%PRS 42.82
-
CSI 2.15rCSI 1.78%PRS 38.08
-
CSI 2.03rCSI 1.87%PRS 40.59
-
CSI 1.99rCSI 2.38%PRS 25.65
-
CSI 1.96rCSI 1.58%PRS 40.04
-
CSI 1.92rCSI 2.31%PRS 37.82
-
CSI 1.87rCSI 1.96%PRS 39.44
-
CSI 1.81rCSI 3.49%PRS 69.19
-
CSI 1.79rCSI 2.74%PRS 40.06
-
CSI 1.76rCSI 1.54%PRS 29.85
-
CSI 1.7rCSI 1.78%PRS 37.09
-
CSI 1.69rCSI 1.99%PRS 43.37
-
CSI 1.69rCSI 4.61%PRS 79.05
-
CSI 1.69rCSI 4.9%PRS 58.76
-
CSI 1.68rCSI 6.1%PRS 58.36
-
CSI 1.62rCSI 2.04%PRS 52.63
-
CSI 1.6rCSI 2.22%PRS 39.32
-
CSI 1.53rCSI 1.18%PRS 38.08
-
CSI 1.52rCSI 4.36%PRS 56.12
-
CSI 1.51rCSI 2.21%PRS 39.92
-
CSI 1.46rCSI 2.57%PRS 38.39
-
CSI 1.46rCSI 3.7%PRS 36.48
-
CSI 1.44rCSI 1.15%PRS 60.83
-
CSI 1.43rCSI 1.24%PRS 43.32
-
CSI 1.43rCSI 1.8%PRS 48.62
-
CSI 1.43rCSI 9.2%PRS 62.27
-
CSI 1.42rCSI 2.88%PRS 24.06
-
CSI 1.4rCSI 2.16%PRS 37.62
-
CSI 1.39rCSI 2.37%PRS 60.2
-
CSI 1.32rCSI 2.34%PRS 24.77
-
CSI 1.28rCSI 1.72%PRS 41.28
-
CSI 1.22rCSI 1.76%PRS 49.52
-
CSI 1.21rCSI 1.84%PRS 48.14
-
CSI 1.17rCSI 2%PRS 48.63
-
CSI 1.13rCSI 2.92%PRS 70.81
-
CSI 1.08rCSI 1.63%PRS 41.07
-
CSI 0.97rCSI 1.27%PRS 52.26
-
CSI 0.95rCSI 18.05%PRS 83.88
-
CSI 0.87rCSI 4.63%PRS 79.07
-
CSI 0.2rCSI 1.2%PRS 51.7%
-
CSI 0.2rCSI 2.9%PRS 73.5%
-
CSI 0.2rCSI 5.4%PRS 68.2%
-
CSI 0.3rCSI 6.3%PRS 67.5%
-
CSI 0.4rCSI 0.6%PRS 31.4%
-
CSI 0.4rCSI 11.3%PRS 64.8%
-
CSI 0.4rCSI 2.9%PRS 71.3%
-
CSI 0.5rCSI 2.6%PRS 63.6%
-
CSI 0.7rCSI 3.2%PRS 50.7%
-
CSI 0.8rCSI 1.2%PRS 45.9%
-
CSI 0.8rCSI 1.6%PRS 57.4%
-
CSI 0.8rCSI 2.3%PRS 54.3%
-
CSI 0.9rCSI 4.6%PRS 79.1%
-
CSI 1.0rCSI 18.1%PRS 83.9%
-
CSI 1.0rCSI 1.3%PRS 52.3%
-
CSI 1.1rCSI 1.6%PRS 41.1%
-
CSI 1.1rCSI 2.9%PRS 70.8%
-
CSI 1.2rCSI 2.0%PRS 48.6%
-
CSI 1.2rCSI 1.8%PRS 48.1%
-
CSI 1.2rCSI 1.8%PRS 49.5%
-
CSI 1.3rCSI 1.7%PRS 41.3%
-
CSI 1.3rCSI 2.3%PRS 24.8%
-
CSI 1.4rCSI 2.4%PRS 60.2%
-
CSI 1.4rCSI 2.2%PRS 37.6%
-
CSI 1.4rCSI 2.9%PRS 24.1%
-
CSI 1.4rCSI 9.2%PRS 62.3%
-
CSI 1.4rCSI 1.8%PRS 48.6%
-
CSI 1.4rCSI 1.2%PRS 43.3%
-
CSI 1.4rCSI 1.2%PRS 60.8%
-
CSI 1.5rCSI 3.7%PRS 36.5%
-
CSI 1.5rCSI 2.6%PRS 38.4%
-
CSI 1.5rCSI 2.2%PRS 39.9%
-
CSI 1.5rCSI 4.4%PRS 56.1%
-
CSI 1.5rCSI 1.2%PRS 38.1%
-
CSI 1.6rCSI 2.2%PRS 39.3%
-
CSI 1.6rCSI 2.0%PRS 52.6%
-
CSI 1.7rCSI 6.1%PRS 58.4%
-
CSI 1.7rCSI 4.9%PRS 58.8%
-
CSI 1.7rCSI 4.6%PRS 79.1%
-
CSI 1.7rCSI 2.0%PRS 43.4%
-
CSI 1.7rCSI 1.8%PRS 37.1%
-
CSI 1.8rCSI 1.5%PRS 29.9%
-
CSI 1.8rCSI 2.7%PRS 40.1%
-
CSI 1.8rCSI 3.5%PRS 69.2%
-
CSI 1.9rCSI 2.0%PRS 39.4%
-
CSI 1.9rCSI 2.3%PRS 37.8%
-
CSI 2.0rCSI 1.6%PRS 40.0%
-
CSI 2.0rCSI 2.4%PRS 25.7%
-
CSI 2.0rCSI 1.9%PRS 40.6%
-
CSI 2.2rCSI 1.8%PRS 38.1%
-
CSI 2.2rCSI 3.5%PRS 42.8%
-
CSI 2.2rCSI 2.2%PRS 34.3%
-
CSI 2.3rCSI 12.2%PRS 54.7%
-
CSI 2.3rCSI 1.6%PRS 41.2%
-
CSI 2.3rCSI 1.8%PRS 28.5%
-
CSI 2.4rCSI 3.9%PRS 44.6%
-
CSI 2.4rCSI 4.8%PRS 30.6%
-
CSI 2.6rCSI 3.0%PRS 34.6%
-
CSI 2.6rCSI 5.8%PRS 45.3%
-
CSI 2.6rCSI 3.0%PRS 54.2%
-
CSI 2.6rCSI 11.3%PRS 55.2%
-
CSI 2.6rCSI 2.4%PRS 46.3%
-
CSI 2.6rCSI 2.5%PRS 40.7%
-
CSI 2.7rCSI 2.5%PRS 39.3%
-
CSI 2.7rCSI 2.6%PRS 31.1%
-
CSI 2.8rCSI 2.6%PRS 54.1%
-
CSI 2.9rCSI 2.1%PRS 51.7%
-
CSI 2.9rCSI 5.4%PRS 73.8%
-
CSI 2.9rCSI 6.3%PRS 43.3%
-
CSI 3.1rCSI 3.2%PRS 56.8%
-
CSI 3.1rCSI 3.1%PRS 68.1%
-
CSI 3.1rCSI 2.1%PRS 43.6%
-
CSI 3.2rCSI 4.4%PRS 67.4%
-
CSI 3.3rCSI 2.7%PRS 40.4%
-
CSI 3.4rCSI 4.1%PRS 59.3%
-
CSI 3.4rCSI 3.3%PRS 40.1%
-
CSI 3.4rCSI 5.4%PRS 40.4%
-
CSI 3.6rCSI 3.1%PRS 44.3%
-
CSI 3.8rCSI 5.3%PRS 48.9%
-
CSI 3.9rCSI 3.8%PRS 54.3%
-
CSI 4.0rCSI 3.1%PRS 45.5%
-
CSI 4.0rCSI 2.3%PRS 53.3%
-
CSI 4.0rCSI 3.7%PRS 59.7%
-
CSI 4.1rCSI 3.1%PRS 51.0%
-
CSI 4.2rCSI 5.7%PRS 44.0%
-
CSI 4.2rCSI 24.2%PRS 50.5%
-
CSI 4.2rCSI 8.2%PRS 41.3%
-
CSI 4.3rCSI 5.5%PRS 37.8%
-
CSI 4.3rCSI 3.6%PRS 44.6%
-
CSI 4.8rCSI 17.0%PRS 76.6%
-
CSI 5.4rCSI 7.5%PRS 60.0%
-
CSI 5.5rCSI 24.3%PRS 34.3%
-
CSI 5.7rCSI 4.5%PRS 60.8%
-
CSI 5.8rCSI 29.3%PRS 49.9%
-
CSI 5.9rCSI 6.6%PRS 55.3%
-
CSI 6.2rCSI 16.5%PRS 52.9%
-
CSI 6.7rCSI 4.4%PRS 65.7%
-
CSI 6.8rCSI 8.2%PRS 46.5%
-
CSI 6.9rCSI 15.4%PRS 45.5%
-
CSI 7.0rCSI 5.3%PRS 50.0%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 2040651807
Symbol: LYAR_HUMAN
Name: Cell growth-regulating nucleolar protein
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 11230166
Title: Towards a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs.
PubMed ID: 11230166
DOI: 10.1101/gr.gr1547r
PubMed ID: 14702039
Title: Complete sequencing and characterization of 21,243 full-length human cDNAs.
PubMed ID: 14702039
DOI: 10.1038/ng1285
PubMed ID: 15815621
Title: Generation and annotation of the DNA sequences of human chromosomes 2 and 4.
PubMed ID: 15815621
DOI: 10.1038/nature03466
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 12429849
Title: Functional proteomic analysis of human nucleolus.
PubMed ID: 12429849
PubMed ID: 18669648
Title: A quantitative atlas of mitotic phosphorylation.
PubMed ID: 18669648
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 24495227
Title: Human cell growth regulator Ly-1 antibody reactive homologue accelerates processing of preribosomal RNA.
PubMed ID: 24495227
DOI: 10.1111/gtc.12129
PubMed ID: 24990247
Title: Lyar, a cell growth-regulating zinc finger protein, was identified to be associated with cytoplasmic ribosomes in male germ and cancer cells.
PubMed ID: 24990247
PubMed ID: 25218447
Title: Uncovering global SUMOylation signaling networks in a site-specific manner.
PubMed ID: 25218447
DOI: 10.1038/nsmb.2890
PubMed ID: 25092918
Title: Human fetal globin gene expression is regulated by LYAR.
PubMed ID: 25092918
DOI: 10.1093/nar/gku718
PubMed ID: 26203195
Title: Nucleolar GTP-binding protein-1 (NGP-1) promotes G1 to S phase transition by activating cyclin-dependent kinase inhibitor p21 Cip1/Waf1.
PubMed ID: 26203195
PubMed ID: 28686580
Title: Upregulation of LYAR induces neuroblastoma cell proliferation and survival.
PubMed ID: 28686580
DOI: 10.1038/cdd.2017.98
PubMed ID: 28112733
Title: Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.
PubMed ID: 28112733
DOI: 10.1038/nsmb.3366
PubMed ID: 31413131
Title: LYAR suppresses interferon-beta induction by targeting phosphorylated IRF3.
PubMed ID: 31413131
DOI: 10.1128/jvi.00769-19
Sequence Information:
- Length: 379
- Mass: 43634
- Checksum: AF159483CF93ECB6
- Sequence:
MVFFTCNACG ESVKKIQVEK HVSVCRNCEC LSCIDCGKDF WGDDYKNHVK CISEDQKYGG KGYEGKTHKG DIKQQAWIQK ISELIKRPNV SPKVRELLEQ ISAFDNVPRK KAKFQNWMKN SLKVHNESIL DQVWNIFSEA SNSEPVNKEQ DQRPLHPVAN PHAEISTKVP ASKVKDAVEQ QGEVKKNKRE RKEERQKKRK REKKELKLEN HQENSRNQKP KKRKKGQEAD LEAGGEEVPE ANGSAGKRSK KKKQRKDSAS EEEARVGAGK RKRRHSEVET DSKKKKMKLP EHPEGGEPED DEAPAKGKFN WKGTIKAILK QAPDNEITIK KLRKKVLAQY YTVTDEHHRS EEELLVIFNK KISKNPTFKL LKDKVKLVK